Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. - Wikidata - awgldk - TriplyDB

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

http://www.wikidata.org/entity/Q34430888

about

Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells.A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon α.Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML).Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for therapeutics and vaccine design.Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment The paradox of response and survival in cancer therapeutics NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients.Chronic myelogenous leukemia: treatment and monitoring.STI-571 in chronic myelogenous leukaemia.The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia.Current CML therapy: progress and dilemma.Advances in targeted therapy for chronic myeloid leukemia.Cancer stem cells: are we missing the target?Cancer Stem Cells: From Bench to Bedside Concise review: Emerging concepts in clinical targeting of cancer stem cells Interferon alpha and T-cell responses in chronic myeloid leukemia.Personalized medical treatment strategies for patients with chronic myeloid leukemia.The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Re-emergence of interferon-α in the treatment of chronic myeloid leukemia Immunotherapeutic approaches in chronic myelogenous leukemia.ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines Imatinib mesylate for the treatment of chronic myeloid leukemia.Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.Interferon alfa versus interferon alfa plus cytarabine combination therapy for chronic myeloid leukemia: a meta-analysis of randomized controlled trials.Do we have to kill the last CML cell?Insights into the stem cells of chronic myeloid leukemia.Clinical trials in chronic myeloid leukemia.

P2860

Q24685070-6F3B7262-FC70-4E9B-B877-D3855B0F999E Q28178372-05FCAC54-F25C-4B0D-8AF2-C0942E4DCBFC Q28476476-C51EF787-5C9A-481F-A87E-1BB26F6A5246 Q33364273-0E7B47DE-1616-474D-93C2-F53E3CBEF719 Q33587624-3F69DB1E-F54C-40F0-9FE9-903740A92284 Q33632220-A8161D94-B468-4F4E-9284-D9995A7794FF Q33644438-EFAC33D2-FED2-435A-867E-5C4DB8DF9980 Q34032263-39B647FE-F47E-4BE0-A3F8-747D068CBD66 Q34055591-11E1C339-0B2A-40F1-9431-09BEDF3F0F18 Q34106393-97CD3297-EDC3-4CC0-92F5-50F68E07004D Q34416807-7EA3F252-CB25-4EE4-8A14-3AFA4DE66A17 Q34449433-6A838165-B62D-480A-B6CA-662A5A500F67 Q34522789-80F1FA94-0046-4A8A-AD59-551191955FB1 Q34547402-089028B9-F25A-4CBF-9566-99228ECA2C80 Q34617628-1178FA49-1127-4221-8EA6-03E14474E0C3 Q34929139-E4B0C1DE-FCCF-49AA-8B00-573E3643995B Q35022540-9405D5F4-B5D8-4944-8388-3B9B593BAD0C Q35034528-854F55F2-DCF2-4EBD-8057-B1A26F0E2565 Q35083184-4C49F106-57F5-4266-A16B-71D7A8196D07 Q35102183-7057DA69-65BE-488D-8DC6-55E1101B6AC3 Q35104353-D8BA1DA2-8FEA-4A50-AE8D-213501842FC3 Q35134977-274D8CF6-4CE3-4790-BE6C-467648D27BA0 Q35160190-D5A15BB7-6E9C-4908-AEC2-A346738AA431 Q35752241-72DEF74A-7557-4DE0-B30D-F6BFFF5C9C29 Q35765724-E2834E3A-8425-40BC-9E44-247951612557 Q35971159-73F4F4A3-6D97-47E6-9C22-4E212B44368F Q35994924-7381A61B-3B53-49C2-8A80-3CB176D994B7 Q36118424-3190B5D1-130A-46FE-9B4C-F3C359FCC00B Q36547224-9CD408F3-8E6F-4522-A55B-932D51929F89 Q36822880-DD6E9B39-00D7-4E58-B844-BF4F52AF811F Q36989407-73D37AAE-86EE-4238-BE25-DC08882FE0E0 Q37132861-31D7B099-0C20-4BE9-AE68-A42B6FF8332D Q37162871-1D2CAD2D-64B5-4F60-8951-FBD4C173604C Q37183434-9EDD808D-41CA-466A-A102-A6D22B00A96F Q37539158-BA8E2E61-A05E-4182-85C2-A4F7186AECE7 Q37579983-2778092B-253B-436F-BD8F-007612249B03 Q37642508-44464733-B3E8-47FF-91EC-97189F35AB08 Q37789148-75895FD6-91C3-4872-9BED-14DF1D21804E Q37791423-5507882A-2C67-4582-828E-C432826B5D44 Q37994134-890AB0E5-CCE0-4F28-901B-4DDC138F2F80

P2860

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

http://www.wikidata.org/entity/Q34430888

description

2001 nî lūn-bûn

@nan

2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Chronic myeloid leukemia and i ...... mplete cytogenetic responders.

@ast

Chronic myeloid leukemia and i ...... mplete cytogenetic responders.

@en

Chronic myeloid leukemia and i ...... mplete cytogenetic responders.

@nl

type

label

Chronic myeloid leukemia and i ...... mplete cytogenetic responders.

@ast

Chronic myeloid leukemia and i ...... mplete cytogenetic responders.

@en

Chronic myeloid leukemia and i ...... mplete cytogenetic responders.

@nl

prefLabel

Chronic myeloid leukemia and i ...... mplete cytogenetic responders.

@ast

Chronic myeloid leukemia and i ...... mplete cytogenetic responders.

@en

Chronic myeloid leukemia and i ...... mplete cytogenetic responders.

@nl

P1433

Q34430888-3541060C-976D-4B56-90B0-E326656D11EC

P1476

Q34430888-6B229FFB-CAA3-467D-82A3-E1219683624E

P2093

Q34430888-0BA7CA93-DF0B-4613-BCFB-35FDA2D7A364

Q34430888-0D705865-24C9-4DB2-B823-4BD73B9880B9

Q34430888-25154893-1DFC-42B7-8D1E-75FAB80E0038

Q34430888-2798CB39-F5A0-426E-9D39-525A872775B6

Q34430888-4D24E35B-4A62-4969-BCC3-97D8B3588298

Q34430888-50756AD3-093F-4A99-A4AC-9CBA6E1DCDCD

Q34430888-59ECEAF4-C301-482F-9358-82BF8083240A

Q34430888-60677774-15ED-4F7E-AD01-55C65C7F09B3

Q34430888-60FA8A0B-9303-42ED-B852-959D31F492B9

Q34430888-66EFC704-4936-4A69-ABD5-664F4788D9C7

P304

Q34430888-349040B7-C985-439E-B1A5-E1F7AFFA1CE2

P31

Q34430888-E02D04FF-382B-4B0E-9C31-5C6DB075BFA5

P356

Q34430888-7D42032E-5F8D-48F3-B42E-C5E93C6AA963

P407

Q34430888-B2355CC9-49C9-417D-B579-3C8F8D9512C3

P433

Q34430888-B3D90683-CB67-4697-BB54-15E2460411B0

P478

Q34430888-278A93BF-8A0E-4F3A-AFC2-3E3C8BA20489

P50

Q34430888-4972CBC1-8DB3-47C4-8B1E-3C4E203618E6

Q34430888-53CCD8B9-3A4E-4140-8ECD-BE3EA2F25106

Q34430888-8F8C4641-F732-4521-981F-C4E97D00463F

Q34430888-DB341D61-43BE-450F-AE09-38169FC5B64D

P577

Q34430888-24CD0BEC-0AD0-4DF8-A358-B28B6DB52C90

P5875

Q34430888-8EEAC9F6-7865-4427-92D1-6ECE1674F914

P698

Q34430888-E7EBF41A-3D73-46A0-A25F-278647F9B036

P921

Q34430888-8E797B80-801D-45CB-919E-435A9BBFB8F5

Q34430888-ECC26039-9BEF-49A8-B827-D3D2268159A4

P356

BLOOD.V98.10.3074

P1433

P1476

Chronic myeloid leukemia and i ...... mplete cytogenetic responders.

@en

P2093

A Louwagie

http://www.w3.org/2001/XMLSchema#string

A de Vivo

http://www.w3.org/2001/XMLSchema#string

Australian CML Study Group

http://www.w3.org/2001/XMLSchema#string

B Simonsson

http://www.w3.org/2001/XMLSchema#string

E Montefusco

http://www.w3.org/2001/XMLSchema#string

E Trabacchi

http://www.w3.org/2001/XMLSchema#string

Europena Study Group on Interferon in Chronic Myeloid Leukemia

http://www.w3.org/2001/XMLSchema#string

F X Mahon

http://www.w3.org/2001/XMLSchema#string

France Intergroup of CML

http://www.w3.org/2001/XMLSchema#string

G Alimena

http://www.w3.org/2001/XMLSchema#string

P304

3074-3081

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD.V98.10.3074

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Hochhaus

Francesca Bonifazi

Giuseppe Saglio

François Guilhot

P577

2001-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11656742

http://www.w3.org/2001/XMLSchema#string

P698

11698293

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia